Yordanova, Anna <br/><br/>
Sorafenib in patients with refractory or recurrent multiple myeloma.  [electronic resource] 

 -  Hematological oncology  Dec 2013 
 - 197-200 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1099-1069 
<br/><br/><label>Standard No.: </label>10.1002/hon.2043  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Combined Modality Therapy<br/>Drug Eruptions--etiology<br/>Drug Resistance, Neoplasm<br/>Fatigue--chemically induced<br/>Female<br/>Hematologic Diseases--chemically induced<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Interferon-alpha--therapeutic use<br/>Lenalidomide<br/>Male<br/>Middle Aged<br/>Molecular Targeted Therapy<br/>Multiple Myeloma--drug therapy<br/>Neoplasm Proteins--antagonists & inhibitors<br/>Niacinamide--adverse effects<br/>Pain--chemically induced<br/>Phenylurea Compounds--adverse effects<br/>Prospective Studies<br/>Protein Kinase Inhibitors--adverse effects<br/>Recurrence<br/>Remission Induction<br/>Salvage Therapy<br/>Sorafenib<br/>Thalidomide--analogs & derivatives<br/>Treatment Outcome